DR REDDYS LABORATORIES LTD DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Dr. Reddy's Q4 Revenue Decreases By 11.51%, PAT Plunges 86%

12 May 2026

// BUSINESS STD

Dr. Reddy's To Join HSBC, Bank Of America Investor Conferences

12 May 2026

// INDPHARMAPOST

Dr. Reddy's, Nestlé Bolster Diabetes, Obesity Nutrition space

08 May 2026

// ECONOMICTIMES

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

CPhI North America

Attending

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

2 Vlog #PharmaReel, 8 Corporate Content #SupplierSpotlight, 12 Data Compilation #PharmaFlow, 1111 News #PharmaBuzz

media
2 Vlog #PharmaReel
8 Corporate Content #SupplierSpotlight
12 Data Compilation #PharmaFlow
1111 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

330 All APIs, 162 USDMF, 40 CEP/COS, 34 JDMF, 114 EU WC, 145 KDMF, 155 NDC API, 146 Listed APIs

330 All APIs
162 USDMF
40 CEP/COS
34 JDMF
114 EU WC
145 KDMF
155 NDC API
146 Listed APIs

DEVELOPMENTS

401 Drugs in Development

401 Drugs in Development

FINISHED DOSAGE FORMULATIONS

837 FDF Dossiers, 595 FDA Orange Book, 5 Europe, 58 Canada, 179 Listed Dossiers

837 FDF Dossiers
595 FDA Orange Book
5 Europe
58 Canada
179 Listed Dossiers

KEY PRODUCTS

Atorvastatin, Azacitidine, Bempedoic Acid, Cabozantinib, Carfilzomib, Clopidogrel, Clopidogrel Besylate, Dabigatran Etexilate Mesylate, Dapagliflozin, Dapagliflozin Propanediol Monohydrate, Empagliflozin, Enzalutamide, Eribulin, Eslicarbazepine Acetate, Ezetimibe, Gemcitabine, Ketorolac Trometamol, Levetiracetam, Lumateperone Tosylate, Lurasidone Hydrochloride, Mirabegron, Naproxen, Naproxen Sodium, Nilotinib, Nizatidine, Olaparib, Palbociclib, Perfluorohexyloctane, Pioglitazone, Pioglitazone Hydrochloride, Pregabalin, Rivaroxaban, Sacubitril-Valsartan, Sitagliptin Hydrochloride, Sitagliptin Malate, Sitagliptin Phosphate, Sumatriptan, Tucatinib, Voclosporin, Vonoprazan Fumarate, Xanomeline

INSPECTIONS & REGISTRATIONS

83 FDA, 36 EDQM, 18 GDUFA, 10 Third-Party Audit

inspections
83 FDA
36 EDQM
18 GDUFA
10 Third-Party Audit

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

About

Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms.

Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale

CPhI North AmericaCPhI North America

Industry Trade Show

Attending

02-04 June, 2026

Philadelphia, U.S.A
CPhI KoreaCPhI Korea

Industry Trade Show

Attending

25-27 August, 2026

Seoul, Korea
CPhI MilanCPhI Milan

Industry Trade Show

Booth #5D18

06-08 October, 2026

Milan, Italy

CONTACT DETAILS

Click the arrow to open the dropdown

$Dr. Reddy\$

Country

India

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana-500 034

Telephone

+91 4049002900

API@drreddys.com

Website

https://api.drreddys.com/

https://www.linkedin.com/company/dr--reddys-laboratories

YouTube

http://www.youtube.com/@drreddys

Digital content

Explore the latest content creation from this company

VLOG #PharmaReel

Leading Supplier of APIs for 40+ Years

Dr. Reddy's delivers unmatched expertise with 40+ years as a leading API supplier, 8 world-class manufacturing facilities across three continents, specialized mastery of complex peptides and HPAPIs, and 1,900+ global DMFs — all backed by certifications from the world's most stringent regulatory authorities.

Impressions: 1149

CORPORATE CONTENT #SupplierSpotlight

Product List 2026

Open PDF

Upload

Corporate Presentation

Open PDF

Upload

FDF Product List 2026

Open PDF

Upload

API Product List 2026

Open PDF

Upload

Atorvastatin Calcium Trihydrate USDMF

Open PDF

Upload

Products Under Development 2026

GMP Certificate 2024

Dr. Reddy's - About Us

DATA COMPILATION #PharmaFlow

CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

PharmaCompass is introducing a new regulatory update that tracks developments in Certificates of Suitability to the Monographs of the European Pharmacopoeia, referred to as CEPs. These certificates are a critical regulatory instrument in the global pharmaceutical supply chain.Also known as a Certification of Suitability (COS), CEPs are issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM), with or without inspection of the manufacturing site. A CEP must be renewed every five years from its original issue date to remain valid, regardless of any revisions made during the interim period. However, a CEP does not replace Good Manufacturing Practice certification.CEPs are recognized as a trusted reference for API quality, thereby simplifying global registration strategies. Apart from Europe, the CEP system is widely used by many regulatory authorities, including those in Canada, Australia, Brazil, Singapore and South Africa. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)CEP 2.0 enhances regulatory clarity, brings efficiency, global interoperability There are several types of CEPs, depending on the nature of the substance and evaluation. The most common type is the Chemical CEP, which confirms that a chemically synthesized API meets standards for purity and impurity control. Then there are Herbal CEPs for herbal substances and preparations.Another key category is the TSE CEP, which addresses risks associated with transmissible spongiform encephalopathies in animal-derived materials. In addition, there are Combined CEPs that may cover multiple aspects, such as chemical quality, TSE risk, and sterility. However, biological products such as vaccines and blood products fall outside the scope of the CEP framework.In 2023, the CEP system underwent a major transformation with the introduction of CEP 2.0, which marks a shift from a largely document-based system to a more structured, transparent, and digitally aligned model. This makes it easier for companies to manage compliance while improving trust among global regulators.While increasing data and compliance requirements for API manufacturers, CEP 2.0 enables better regulatory clarity, streamlined dossier integration, and stronger global acceptance. Overall, CEP 2.0 is designed to enhance regulatory clarity while making the system more efficient and globally interoperable. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Indian firms issued maximum CEPs; Sun Pharma and its subsidiaries, Jubilant Biosys top listIndia topped the charts for CEPs issued, both in terms of new CEPs and revisions in the first quarter (Q1) of 2026. Indian companies were issued 81 new CEPs in Q1 2026 (as against 40 in Q1 2025) and 203 revisions (as against 129 in Q1 2025). In comparison, Chinese companies were issued 42 new CEPs in Q1 2026 (against 25 in Q1 2025) and 53 revisions (against 67 in Q1 2025). Italy came a distant third, followed by Germany and Spain.India’s Sun Pharmaceuticals and its subsidiaries topped the list of companies with the maximum number of CEPs issued— while no new CEP was issued, 27 CEPs were revised in Q1 2026. At second place was Jubilant Biosys — 21 CEPs were revised in Q1 2026.In terms of products, the maximum CEPs were issued for amlodipine besylate (a calcium channel blocker used for treating hypertension), followed by sitagliptin phosphate (a type 2 diabetes medicine) and pregabalin (a drug used to treat neuropathic pain, fibromyalgia, seizures, and generalized anxiety disorder). Both amlodipine besylate and sitagliptin phosphate had not been issued new CEPs or revisions in Q1 2025. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)EDQM introduces new guidelines to accelerate CEP assessments The EDQM charges fees for various services related to CEPs that depend on the type of request or regulatory activity involved. In general, fees apply to handling CEP applications, revisions or renewals and for offering technical advice (where applicants seek scientific or regulatory guidance).In March 2026, the EDQM introduced two new guidelines aimed at accelerating CEP assessments. The first is a reliance-based assessment pathway, which allows regulators to leverage prior approvals from trusted authorities, such as those in the EU, UK, Australia, Canada, and the WHO pre-qualification program. The second is a fast-track assessment route designed to expedite reviews in situations such as medicine shortages and to support initiatives like the EU Critical Medicines Act.Timelines have been significantly compressed under these new pathways. Initial evaluations are completed within 46 working days, compared to up to 115 days under the standard procedure. Applicants are given 30 calendar days to respond to queries, after which regulators complete the final assessment within 23 working days.Another important regulatory update relates to electronic submissions. From April 1, 2026, the EDQM will reject non-compliant CEP applications at the point of submission. All applications must include a validated electronic Common Technical Document (eCTD) dossier along with a proper validation report, submitted in line with the updated Common European Submission Portal (CESP) guidelines. Taken together, these developments signal a more rigorous yet efficient CEP ecosystem. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Our viewThe shift to CEP 2.0 signals a move toward greater transparency, digitalization, and global regulatory alignment. Though enhanced disclosure and stricter e-submission requirements may increase the compliance burden, especially for smaller manufacturers, the long-term gains are expected to be significant. Going forward, companies that invest in data quality and regulatory readiness stand to gain from these changes.

Impressions: 1824

DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

The third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA). DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug productsA total of 323 Type II DMFs were submitted during this period, as opposed to 309 submissions in Q3 2024, marking an increase of 4.53 percent. This is the second highest number since 2018. In Q1 2025, 339 Type II filings were recorded.Across all DMF types (II, III, IV, and V), 479 DMFs were filed in Q3 2025, compared to 394 in Q3 2024, representing a 21.57 percent increase. Out of the 323 Type II DMFs submitted in Q3 2025, 40 had completed their review by the end of Q3, reflecting a processing lag between submission and review completion. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available)China maintains its lead while India posts double-digit growth in DMF submissions China and India continued to dominate DMF submissions in Q3 2025. China retained the top spot with 153 Type II DMFs, matching its submission count from Q3 2024. India recorded 131 DMFs, marking a 20.18 percent increase over 109 filings during the corresponding period last year.The United States stood a distant third with 17 filings, compared to 13 in Q3 2024. Among European nations, Italy recorded eight DMFs, doubling its 2024 tally. The Netherlands filed four, up from three. Spain submitted only one DMF, as against seven submitted in Q3 2024. Taiwan made three filings, up from one submitted in Q3 2024. Together, India, China and Taiwan accounted for about 88.9 percent of all Type II DMFs filed during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) China’s Suzhou Ryway Biotech tops corporate tally; India’s Hetero, Biophore followChina’s Suzhou Ryway Biotech led the company-wise tally with 12 DMF submissions in Q3 2025. The company had not filed any DMFs in Q3 2024.India’s Hetero Group followed with nine DMFs, maintaining the same number of filings as Q3 2024. Biophore India Pharmaceuticals ranked third with six DMFs, doubling its count from three last year.Other notable contributors include Sai Sreyas Pharmaceuticals (India) and Shanghai Haoyuan Chemexpress (China), with five DMFs each. Companies such as SNJ Group, Lunan Pharmaceutical, Allsino Pharmaceutical, Shankus Pharma, Jiangxi Xinganjiang Pharmaceutical, Sunpure Extracts, Lee Pharma, Umedica Laboratories, Linhai Tianyu Pharmaceutical and Maithri Drugs filed four DMFs each. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) Olaparib, semaglutide lead molecular filings; Dr. Reddy’s files DMF for edoxaban & tucatinibDr. Reddy’s Laboratories also featured among key DMF filers in Q3 2025, submitting two DMFs — for edoxaban tosylate monohydrate and tucatinib copovidone. Edoxaban tosylate monohydrate (marketed as Savaysa by Daiichi Sankyo) is a prescription anticoagulant used to reduce the risk of stroke and to treat deep vein thrombosis and pulmonary embolism. Patent exclusivity for Savaysa extends until October 2026 in the United States, with no generic currently available.In terms of molecules, the highest number of DMFs were filed for olaparib, semaglutide, ruxolitinib phosphate, ferric carboxymaltose, and vismodegib, with three DMFs each in Q3 2025.Olaparib, sold by AstraZeneca under the brand name Lynparza, saw DMFs being filed by BDR Lifesciences and Intas Pharmaceuticals from India, and by ScinoPharm Taiwan during the quarter.Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, continued to draw strong interest from API manufacturers. DMFs for semaglutide were filed by three Chinese companies: Yangzhou Aurisco Pharmaceutical, Zhejiang Peptites Biotech, and Fujian Genohope Biotech.Ruxolitinib phosphate, marketed by Incyte as Jakafi, saw three DMFs. Three Indian companies — Alembic Pharmaceuticals, Valary Labs, and Devi Pharmatech — filed DMFs for this API in Q3 2025. Other molecules that received multiple DMF submissions include ferric carboxymaltose (used to treat iron-deficiency anemia) and vismodegib (an oral therapy for basal-cell carcinoma). View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) First-time DMF filings span 17 companies; India leads with nine first-time DMFs The quarter saw first-time DMF filings from 17 companies. India took a lead here with nine first-time DMF filings, followed by China (six), and the US (two).The DMF filings in this quarter included inclisiran sodium (filed by Aurisco Pharmaceutical of China), pacritinib citrate (by TAPI Nl B.V. of the Netherlands), and vosoritide (by Apicore LLC of the US).Out of the 19 first-time DMFs filed in Q3 2025, four completed their Generic Drug User Fee Amendments (GDUFA) review process during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2026: The FDA Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry.Fee rates for fiscal year 2026 were published on July 30, 2025. FDA has revised fees under GDUFA III across all categories. While there is a slight increase in the DMF fee from US$ 95,084 in 2025 to US$ 102,584 in 2026, the ANDA fee has seen a sharp rise: from US$ 321,920 in 2025 to US$ 358,247 in 2026.FY 2025 and FY 2026 User Fee Rates Generic drug fee category Fees rates for FY 2025 Fees rates for FY 2026 Applications: Abbreviated New Drug Application (ANDA) US$ 3,21,920 US$ 3,58,247 Drug Master File (DMF) US$ 95,084 US$ 1,02,584 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 41,580 US$ 43,549 API—Foreign US$ 56,580 US$ 58,549 Finished Dosage Form (FDF)—Domestic US$ 2,31,952 US$ 2,38,943 FDF—Foreign US$ 2,46,952 US$ 2,53,943 Contract Manufacturing Organization (CMO)—Domestic US$ 55,668 US$ 57,346 CMO—Foreign US$ 70,668 US$ 72,346 GDUFA Program: Large size operation generic drug applicant US$ 18,91,664 US$ 19,18,377 Medium size operation generic drug applicant US$ 7,56,666 US$ 7,67,351 Small business generic drug applicant US$ 1,89,166 US$ 1,91,838 Our viewFor several years prior to the pandemic, India had a lead in Type II DMF submissions. In recent years, China has surpassed India in DMF filings. But Q3 2025 numbers indicate that Indian drugmakers are fast catching up. Since DMFs establish trust in APIs from across the world, we feel this healthy competition between drugmakers from the two countries is good for the global pharmaceutical industry.

Impressions: 4458

US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities

The pharmaceutical industry in the United States continued to grapple with drug shortages during the first quarter (Q1) of 2025. According to the American Society of Health‑System Pharmacists (ASHP), the total number of active shortages stood at 270 as of March 31, 2025 — only slightly below the 277 reported in September 2024, but down 16.4 percent from an all‑time high of 323 reported in Q1 2024.These numbers imply that while dramatic surges in drug shortages may have subsided, underlying vulnerabilities in manufacturing, supply chains, and raw‑material sourcing continue to frustrate efforts towards a durable resolution.A deeper analysis of these drug scarcities reveals that 41 percent of the 270 active shortages first emerged in 2022 or earlier. This implies that many of the current disruptions have become chronic in nature and are exerting pressure on pharmacy operations. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available)CNS drugs dominate with 49 meds in short supply; antimicrobials face shortage of 39 drugsClass‑specific analysis reveals that central nervous system (CNS) agents remained the most disrupted category, with 49 distinct CNS drugs having faced scarcities during Q1. This group spans anxiolytics (anti-anxiety drugs) such as clonazepam and flurazepam, sedatives like lorazepam and midazolam, and stimulants such as methylphenidate and lisdexamfetamine. These shortages pose two challenges — controlling seizures and managing sedation in acute care settings. After CNS agents, antimicrobials was the second‑largest category, with shortages affecting 39 drugs. Key antibacterial and anti-fungal agents such as cefotaxime sodium powder for injection, clindamycin phosphate, rifampin, and metronidazole find themselves on ASHP’s active‑shortage roster, threatening both routine hospital protocols and emergency sepsis management.Fluids and electrolytes occupied the third spot, with 29 items facing shortage in Q1 2025. Hormone agents, including insulin analogs, ranked fourth with 24 drugs in short supply.Chemotherapy medications rounded out the top five categories, with 23 antineoplastic agents (a broad class of medications used to treat cancer) flagged as actively constrained in Q1 2025. Notable shortages included azacitidine, carboplatin, methotrexate, and streptozocin. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) US faces 26 new shortages; Pharmacopeia list warns of 100 vulnerable medicationsThe first quarter saw the emergence of 26 new shortage declarations, emphasizing that even drugs previously deemed reliably sourced can fall into scarcity. The US has been facing a shortage of attention deficit hyperactivity disorder (ADHD) drugs since 2022. The new shortages included ADHD transdermal patch methylphenidate, peginterferon alfa‑2a (Pegasys) used in chronic hepatitis B and C, and bacitracin ophthalmic ointment.The fragility of the pharmaceutical supply chains has been particularly evident in the aftermath of natural disasters. Hurricane Helene’s flooding at Baxter’s Marion, North Carolina, facility deeply affected IV‑solution supply lines. Baxter supplies roughly 60 percent of the US’ IV fluids and the ASHP report listed “hurricane” as the reason behind nine percent of drug shortages, as of January 2025.Regulatory and policy interventions continue to evolve. The US Pharmacopeia’s inaugural Vulnerable Medicines List, launched in 2025, identifies 100 drugs at the highest risk of future shortages, with a particular focus on injectables (comprising 71 percent of the list) and essential hospital care.Antibiotics, medications for pain management and oncology are the other drugs on the list. Although 61 percent of these vulnerable medicines were not in active shortage at the time of listing, their inclusion is intended to galvanize manufacturers and purchasing organizations to bolster inventories.Meanwhile, the Government Accountability Office in the US has called on the Department of Health and Human Services (HHS) to establish a formal coordination mechanism, warning that elimination of the HHS supply‑chain coordinator role in May 2025 risks fragmenting federal response efforts. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Global shortages mirror US patterns; Europe launches monitoring platform Globally, we notice comparable trends. For instance, Europe has rolled out the European Shortages Monitoring Platform (ESMP) this year in order to centralize shortage reporting across member states. Critical‑medicine shortages in the EU — in areas such as oncology, ADHD, and critical care analgesics — mirror US patterns. The European Medicines Agency’s shortage list currently holds 37 human drugs.According to Health Canada’s May 12, 2025 update, its Tier 3 list had 18 drug shortages that are considered to have the greatest impact on Canada’s drug supply and health‑care system. Tier 3 designation is based on medical necessity and minimal availability of alternatives.In hematology and oncology, scarcity of essential drugs like Oncaspar for acute lymphoblastic leukemia, idarubicin and lomustine for leukemias and brain tumors, anagrelide for thrombocythemia, and preservative‑free methotrexate for various malignancies underscore the impact these drug shortages can have on treatment. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Our viewThe global pharma supply chain is dealing with a fresh wave of uncertainties, especially with the likelihood of tariffs on drugs imported into the US. Analysts warn that the proposed pharmaceutical tariffs could exacerbate supply issues.Over 50 percent of drugs used in the US are manufactured abroad. Generic sterile injectable drugs — like chemotherapy medications and IV saline — are particularly vulnerable due to their complex manufacturing processes and low profit margins. Generic drugs (which account for 90 percent of prescriptions filled in the US) could face increased pressure, as many rely on raw materials from China and India. This could result in more severe drug shortages in the future.

Impressions: 5140

DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions

The first quarter (Q1) of 2025 witnessed an impressive surge in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA), signaling a robust expansion in pharmaceutical development activities, the looming threat of tariffs notwithstanding.A total of 339 Type II DMFs were submitted during this period, as opposed to 235 submissions in Q1 2024, marking an exceptional increase of 44.26 percent. PharmaCompass’ data suggests that this is a record high for any first quarter.Overall, 440 DMFs were submitted across all categories (Types II, III, IV, and V) during Q1 2025, compared to 353 in the same period last year — representing a 24.65 percent increase.India and China continued to dominate the DMF landscape. India led with 162 submissions in Q1 2025, posting a remarkable 51.4 percent increase over 107 submissions recorded in Q1 2024. China followed with 135 submissions, representing a 33.66 percent increase over the 101 filings in Q1 2024.Taiwan sprung a surprise as a distant third. It made 12 DMF submissions in Q1 2025, as opposed to just one in Q1 2024. Western countries like the US, Spain, Germany, and Italy have maintained relatively stable or declining submission rates. Only the Netherlands showed significant growth with four DMF submissions in Q1 2025, up from zero in Q1 2024. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available)Indian giants MSN, Aurobindo, Cipla, Dr Reddy’s lead record-breaking DMF surgeIndia lived up to its “pharmacy of the world” reputation with the highest DMF submissions. In fact, seven of the top eight companies in the DMF tally were headquartered in India. MSN Group, emerged as the unequivocal leader with 23 submissions in Q1 2025, as against 15 in Q1 2024. Aurobindo Pharma increased its DMF activity from seven submissions in Q1 2024 to 12 in Q1 2025. Alivus Life Sciences, formerly known as Glenmark, made a dramatic leap with eight submissions in Q1 2025, quadrupling its previous year’s count of just two. Cipla more than doubled its DMF submissions — from three in Q1 2024 to eight in Q1 2025.Dr. Reddy’s Laboratories, one of India’s largest generic drugmakers, filed seven DMF submissions. The company’s Q1 2025 DMF portfolio includes high-value molecules like deucravacitinib, finerenone, enzalutamide, niraparib tosylate monohydrate, tucatinib, and tizanidine hydrochloride.Dr. Reddy’s has also indicated that they are open to manufacturing in the US. Meanwhile, Hetero Drugs filed seven submissions while Lee Pharma recorded six in Q1 2025.Chinese manufacturer Jiangsu East-Mab Biomedical Technology also established a significant presence with six DMFs. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Semaglutide, finerenone see most DMF submissions; first-time filings surge 64%Semaglutide and finerenone emerged as the most documented molecules in Q1 2025, each garnering nine DMF submissions. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized diabetes management and weight loss treatment, continues to attract significant manufacturer interest. Similarly, finerenone, a non-steroidal drug used in treating chronic kidney disease in type 2 diabetes patients, has garnered attention from manufacturers.Carfilzomib, used in multiple myeloma treatment, secured the third position with five DMF submissions. Deucravacitinib, a novel drug approved for moderate to severe plaque psoriasis, followed with four DMF submissions.There were several molecules with three DMF submissions each. Among them were tapinarof, a novel drug for psoriasis, and tirzepatide, a GLP-1/GIP receptor agonist that has shown remarkable efficacy in diabetes and weight management. During the quarter, 23 molecules received their inaugural DMF submissions. This number has risen by 64 percent since Q1 2024, when only 14 drugs saw their first DMF filings.In Q1 2025, these 23 first-time molecules collectively garnered 30 DMF submissions, with deucravacitinib emerging as the clear leader. Indian companies Dr. Reddy’s Laboratories and Cipla filed DMFs for this plaque psoriasis treatment as did Spain’s Curia and PMC Global.The Q1 2025 roster of first-time DMF filings include retatrutide (another GLP-1 receptor agonist), sotagliflozin, setmelanotide acetate, daridorexant, nusinersen, zavegepant, belzutifan, elacestrant dihydrochloride, selumetinib sulfate, sotorasib, atogepant, omadacycline tosylate, osilodrostat phosphate, ensifentrine, landiolol hydrochloride, maralixibat chloride, maribavir, methyl olivetolate, diazoxide choline, sparsentan, thinnertide, and vismodegib. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Our viewGiven Trump’s rhetoric around tariffs on imported drugs, the record-breaking DMF submissions in Q1 2025 sent out a strong message that the global pharmaceutical industry is willing to take on the complex geopolitical situation with resilience and strategic foresight.On a different note, the rise in DMF filings also indicate increased workload for the FDA staff, as also more inspections by the agency. It seems like more ‘laid off’ FDA employees will be asked to return to work in the coming days.

Impressions: 4697

FDA’s first generic approvals slump 21% in 2024; Novartis’ top seller Entresto, cancer blockbuster Tasigna lead 2024 patent cliff

A watershed moment in the journey of a drug is when it transitions from being a patented, high‐priced innovator product to an affordable generic.Through an inaugural approval, or a “first generic”, the US Food Drug Administration (FDA) permits a manufacturer to market a generic version of a brand‐name drug — a process that, when successful, grants 180 days of exclusivity to the generic sponsor. This exclusivity is especially valuable when the drug in question is a blockbuster.In FDA’s fiscal year 2024 (i.e. from October 1, 2023 to September 30, 2024), the number of first-time generic drug approvals decreased by 21.3 percent — from 89 in FY 2023 to 70 in FY 2024, the lowest in at least nine years.Lupin emerged as a frontrunner in first generics, increasing its approvals from three in FY 2023 to seven in FY 2024, Apotex and Zydus Lifesciences from four to six, and Dr. Reddy’s from two to four. In contrast, Teva, Amneal, and Sun Pharma experienced a decline.Overall, neurology led the way with 10 approvals, while immunology saw eight, including three approvals in dermatology. Oncology and cardiology/vascular disease saw six approvals each. Ophthalmology saw five while psychiatry, and infectious diseases each contributed four approvals. View First Generic Drug Approvals by FDA in FY 2024 (Free Excel Available) Novartis’ top seller Entresto, blockbuster Tasigna among six key drugs hit by generic rivalsIn 2024, the tide turned sharply for Novartis as it lost exclusivity for six of its drugs. Among them was its blockbuster Entresto, that has generated US$ 29.2 billion in revenue so far, including US$ 7.8 billion in 2024.A combination of sacubitril and valsartan, Entresto has transformed heart failure management. Entresto was the primary driver of Novartis’ sales growth last year. It was also one of the 10 drugs selected by the Biden administration in 2023 for Medicare price negotiations. Novartis has been fighting a fierce legal battle to protect Entresto from generic competition. In 2024, Entresto’s generic saga reached a crescendo. Alembic Pharmaceuticals, Laurus Labs, and Crystal Pharmaceutical’s generic versions of Entresto received FDA approval in May last year. But the Swiss drugmaker has noted that as of January 2025, there were no Entresto generics available in the US.Novartis’ Tasigna (nilotinib) has been a cornerstone in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Apotex won approvals for generics of 50 mg, 150 mg, and 200 mg of nilotinib formulations, thereby offering a more affordable option for both adult and pediatric patients. Owing to the generics, Tasigna’s sales fell 10 percent in 2024.Novartis’ Mekinist (trametinib), Votrient (pazopanib), Rydapt (midostaurin), and Promacta (eltrombopag) have long been critical treatments in oncology and hematology. With generic competition hitting these key assets, Novartis is now aggressively forging deals to strengthen its pipeline. View First Generic Drug Approvals by FDA in FY 2024 (Free Excel Available) FDA clears first generics for Neurocrine’s Ingrezza, Supernus’s Gocovri, ALS drugsIn psychiatry, Neurocrine Biosciences’ Ingrezza (valbenazine) capsules have carved out a niche for themselves as a first-in-class treatment for tardive dyskinesia, a movement disorder that can develop as a side effect of long-term use of antipsychotic meds. Two generics for Ingrezza from India’s Zydus and Lupin bagged FDA approval, as Ingrezza sales topped US$ 2.3 billion last year.Zydus also won first generic approval for Supernus Pharmaceuticals’ Gocovri (amantadine) extended-release capsules, which is a treatment of dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy.Four companies received FDA approvals for their first generics of Mitsubishi Tanabe’s patented drug Radicava (edaravone). These are Dr. Reddy’s Laboratories, Gland Pharma (a Fosun Pharmaceutical subsidiary), Hikma and Long Grove. Radicava is a drug that treats amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. Another treatment for ALS from Italfarmaco — Tiglutik (riluzole) — received a first generic when FDA okayed Alkem Laboratories riluzole oral suspension. The med helps slow disease progression. View First Generic Drug Approvals by FDA in FY 2024 (Free Excel Available) Pfizer’s Ibrance, Gilead’s Descovy, Lilly’s Olumiant treatment come under generic pressureIn oncology, Synthon Pharmaceuticals launched its generic version of Pfizer’s Ibrance (palbociclib) tablets. Generating sales of US$ 4.4 billion in 2024, this groundbreaking CDK4/6 inhibitor is Pfizer’s best-selling cancer drug. It has transformed treatment for hormone receptor-positive, HER2-negative advanced breast cancer by halting cancer cell division and significantly extending progression-free survival when combined with endocrine therapy.Descovy, a combination of emtricitabine and tenofovir alafenamide, stands as one of the most important therapies in the fight against HIV infection and related conditions. Originally developed by Gilead Sciences, Descovy has played a pivotal role in modern antiretroviral therapy, contributing US$ 2.1 billion to Gilead’s revenue in 2024. Apotex’s first generic approval for Descovy marked its second copycat for a blockbuster drug in 2024. The other generic approval it got its hands on was for Boehringer Ingelheim’s Pradaxa (dabigatran etexilate), a blood thinner that posted sales of € 845 million (US$ 883 million) in 2023.In immunology, Eli Lilly’s Olumiant (baricitinib) has emerged as an important therapy for treating inflammatory conditions such as rheumatoid arthritis. Aurobindo Pharma bagged FDA approval for generic baricitinib tablets.Ipsen’s Somatuline Depot (lanreotide) injection, a treatment for neuroendocrine tumors and endocrine disorders that generated about € 1.07 billion (US$1.1 billion) in 2023 sales, also has a generic now, with Cipla’s subsidiary InvaGen Pharmaceuticals receiving an FDA approval. View First Generic Drug Approvals by FDA in FY 2024 (Free Excel Available) FDA okays copycats for opioid withdrawal med Lucemyra, weight loss drug Qsymia, contraceptive SlyndFDA also demonstrated a focused commitment to addressing two of the nation’s biggest public health concerns — the opioid crisis and obesity. Lucemyra (lofexidine), originally developed by US WorldMeds, is a non-opioid medication indicated for mitigating symptoms associated with acute opioid withdrawal and facilitating the completion of opioid discontinuation treatment. The introduction of Indoco Remedies’ generic version is poised to expand access to this critical therapy by offering a cost-effective alternative for managing substance use disorders.Vivus’ Qsymia (phentermine/topiramate), a chronic weight management therapy, also received a first generic. Actavis’ generic for Qsymia provides a more accessible option to patients striving to lose weight. Actavis is a subsidiary of Teva.FDA also approved Lupin’s first generic version of Insud Pharma’s Slynd—a progestin‑only contraceptive containing 4 mg drospirenone for use by females of reproductive potential to prevent pregnancy. View First Generic Drug Approvals by FDA in FY 2024 (Free Excel Available) Our viewOver the next two years, several blockbusters such as Novo Nordisk’s Ozempic (semaglutide), AstraZeneca’s Farxiga (dapagliflozin), Bristol Myers Squibb’s Revlimid (lenalidomide) and its Pfizer partnered drug Eliquis (apixaban) stand to lose their patent protection. We expect more patent litigations and some exciting innovations in the generics space.

Impressions: 6122

FDA okays 50 new drugs in 2024; BMS’ Cobenfy, Lilly’s Kisunla lead pack of breakthrough therapies

In 2024, the biopharma industry continued to advance on its robust trajectory of innovation. Though the US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) approved fewer drugs, there was a significant increase in medical breakthroughs.While the CDER approved 50 new drugs in 2024, as compared to 55 in 2023, the CBER granted 14 biologics approvals in 2024, down from 20 in 2023.The European Medicines Agency (EMA) approved 34 new therapies, up from 32 in 2023, while Health Canada granted 28 approvals, down from 38 in 2023.The year saw long-awaited treatments being approved in areas such as schizophrenia and Alzheimer’s disease in the second half (H2) of 2024. In H1 2024, drugs to treat metabolic dysfunction-associated steatohepatitis (MASH) and chronic obstructive pulmonary disease (COPD) had been granted FDA approvals.As the year drew to a close, FDA began approving drugs at a feverish pace, with 29 of the CDER’s 50 approvals coming in H2.Like most years, the landscape of drug approvals was dominated by oncology, with 15 of the 50 drugs (30 percent) approved targeting various forms of cancer. This was followed by dermatology and non-malignant hematology, each accounting for 12 percent of approvals. Notably, small molecules continued to dominate the market, making up for 64 percent of the new drug approvals, while 32 percent were proteins, including monoclonal and bi-specific antibodies. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available)Karuna-BMS’ schizophrenia drug, Lilly’s Alzheimer’s med, Neurocrine’s Crenessity dominate list of pathbreaking approvals in H2Out of the 50 new drugs approved in 2024, CDER identified 24 (48 percent) as first-in-class, showcasing novel mechanisms of action. The most anticipated approval of 2024 was Karuna and Bristol Myers Squibb’s Cobenfy, a groundbreaking treatment for schizophrenia. This fixed-dose combination of xanomeline and trospium chloride represents the first novel mechanism of action in decades for this debilitating psychiatric condition. Analysts forecast peak annual sales of over US$ 3.3 billion for Cobenfy. Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) became the third amyloid-targeting antibody to gain FDA approval. Unlike its predecessors, Kisunla offers a unique limited-duration treatment regimen, allowing patients to discontinue therapy once amyloid levels in the brain drop below a certain threshold. Priced at approximately US$ 32,000 per year, it is positioned as a cost-effective alternative to existing treatments. Analysts estimate peak sales of US$ 2.4 billion for Kisunla.Crenessity (crinecerfont), developed by Neurocrine Biosciences, became the first FDA-approved treatment in decades for classic congenital adrenal hyperplasia (genetic conditions that affect the adrenal glands). Similarly, Vertex’s triple combination therapy of deutivacaftor, tezacaftor & vanzacaftor (Alyftrek) for cystic fibrosis represents a significant advancement in genetic disease treatment. Analysts forecast peak sales exceeding US$ 8.3 billion, underscoring the therapy’s potential to transform patient care.Meanwhile, Bridgebio’s Attruby (acoramidis hydrochloride) emerged as a promising treatment for cardiac amyloidosis, a life-threatening condition. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Roche’s Itovebi, Checkpoint’s Unloxcyt clinch FDA approvals in H2 2024; forecast to achieve blockbuster statusThe dominance of cancer drug approvals reflects the ongoing focus on targeted therapies, immuno-oncology, and precision medicine to improve outcomes for patients with hard-to-treat cancers.Among the year’s notable FDA approvals was Genentech’s Itovebi (inavolisib), another targeted therapy that treats hormone receptor-positive (HR+), HER2-negative breast cancer. Itovebi is a PI3Kα inhibitor designed specifically for patients with PIK3CA mutations, a common driver of resistance to endocrine therapy in breast cancer. It demonstrated a more tolerable safety profile. Roche projects Itovebi’s peak (annual) sales to reach CHF 2 billion (US$ 2.3 billion).Checkpoint Therapeutics’ Unloxcyt (cosibelimab) joined the crowded checkpoint inhibitor market as the eleventh PD-1/PD-L1-targeting monoclonal antibody approved by the FDA. It was granted approval for cutaneous squamous cell carcinoma (cSCC), an aggressive form of skin cancer with high recurrence rates. As compared to other checkpoint inhibitors, like Keytruda (pembrolizumab) and Opdivo (nivolumab), Unloxcyt is likely to offer an advantage in immune activation.FDA also approved Astellas’ Vyloy (zolbetuximab), a first-in-class monoclonal antibody for metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Analysts forecast peak sales of approximately US$ 850 million for Vyloy.Syndax Pharmaceuticals’ Revuforj (revumenib) was approved by FDA to treat a type of acute leukemia in both adults and children. This approval introduces a novel class of medications known as menin inhibitors. These agents are currently in clinical development for the treatment of genetically defined subsets of acute leukemia. These inhibitors function by preventing the activation of cancer growth-related proteins. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Potential blockbusters Lilly’s Ebglyss, Galderma’s Nemluvio lead advances in dermatologyEli Lilly’s Ebglyss (lebrikizumab) garnered significant attention. Approved by FDA for moderate-to-severe atopic dermatitis, this monoclonal antibody introduces a less burdensome dosing regimen compared to its competitors, with maintenance therapy required only once a month. This feature positions it as a potential contender to Dupixent (dupilumab), a market leader in atopic dermatitis. Ebglyss sales are forecast to reach US$ 1.9 billion by 2030.Galderma’s Nemluvio (nemolizumab) secured FDA approval for two indications in 2024 — prurigo nodularis (a chronic disorder of the skin) and moderate-to-severe atopic dermatitis in patients aged 12 years and older. As the first humanized IgG2 monoclonal antibody targeting the IL-31 receptor, Nemluvio directly inhibits the key driver of itch and inflammation in both these conditions. With its unique mechanism and broad dermatology potential, analysts forecast peak sales of approximately US$ 1.66 billion. Ebglyss and Nemluvio underscore the growing importance of biologics in dermatological care.Botanix Pharmaceuticals also made strides in dermatology by clinching an FDA approval for Sofdra (sofpironium) in June. The drug has been okayed for the treatment of primary axillary hyperhidrosis, a condition characterized by excessive sweating.Ascendis Pharma’s Yorvipath (palopegteriparatide), a therapy approved by FDA to treat hypoparathyroidism, is forecast to achieve blockbuster sales of US$ 1.8 billion by 2030, highlighting its potential to transform endocrine care. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Our viewOverall, 2024 was defined by its breakthrough drug approvals. The year also saw significant reduction in complete response letters (CRLs) — they dropped from 43 in 2023 to just 29 in 2024. This suggests improved industry preparedness and alignment with regulatory expectations.The new year began with the approval of Datroway (datopotamab deruxtecan) from AstraZeneca and Daiichi Sankyo, marking a significant advancement in oncology. Several other promising new drugs are coming up for FDA approval this year, such as J&J’s nipocalimab, Vertex Pharmaceuticals’ suzetrigine, Elevar Therapeutics’ rivoceranib/camrelizumab, Sanofi’s fitusiran and GSK’s gepotidacin. Hopefully, the momentum of breakthrough approvals will continue through 2025, political headwinds in the US notwithstanding.

Impressions: 13825

CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025.

Impressions: 6016

Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397 Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17 13 37 Taiwan 9 6 5 4 24 Switzerland 15 4 4 23 France 16 6 22 Japan 18 1 19 United Kingdom 12 1 2 15 Mexico 9 1 1 11 Ireland 5 5 1 11 Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years.

Impressions: 16109

DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024. Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each. The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders). View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453 US$ 3,21,920 Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427 US$ 2,31,952 FDF—Foreign US$ 2,35,427 US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629 US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852 US$ 7,56,666 Small business generic drug applicant US$ 1,72,963 US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.

Impressions: 10440

CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines.

Impressions: 5491

FDA approves record eight biosimilars in H1 2024; okays first interchangeable biosimilars for Eylea

Biologics, or complex drugs that are derived from living organisms, have revolutionized treatment of various conditions such as cancer, autoimmune diseases, and chronic illnesses. In 2023, eight out of 10 of the world’s top-selling drugs were biologics, including Merck’s Keytruda, AbbVie’s Humira, and Sanofi’s Dupixent.Due to their high costs, accessibility of biologics has been a challenge. That’s why biosimilars, or game-changing copycats of biologics that provide highly similar yet more affordable alternatives to established biologics, are becoming popular.The first biosimilar — Sandoz’ Zarxio — was approved by the US Food and Drug Administration (FDA) in 2015. Its reference biologic was Amgen’s Neupogen (filgrastim). Since then, the global market for biosimilars has been growing at an impressive pace — between 2015 and 2020, it grew at a whopping compounded annual growth rate (CAGR) of 78 percent, touching US$ 17.9 billion in size. It is expected to continue growing at a CAGR of 15 percent and reach a size of about US$ 75 billion by 2030.Major biosimilar players include Amgen, Sandoz, Samsung Bioepis, Pfizer, Biocon Biologics, Celltrion, Stada Arzneimittel, Accord Healthcare, Fresenius Kabi, Coherus Biosciences, Apotex, and Sanofi. The increasing demand for biosimilars has propelled growth in contract manufacturing. Some of the leading contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) that manufacture biosimilars are Polpharma Biologics, Catalent, Pfizer CentreOne, Lonza, Boehringer Ingelheim BioXcellence, Thermo Fisher Scientific, WuXi Biologics, and FUJIFILM Diosynth Biotechnologies.Access the Interactive Dashboard for Biosimilar Developments (Free Excel)Amgen, Sandoz top list of ‘approved biosimilars’; FDA okays 8 copycats in H1 2024Over the recent years, regulatory agencies like the FDA and the European Medicines Agency (EMA) have established rigorous approval pathways for biosimilars.Since 2015, FDA has approved 53 biosimilars, while the EMA has approved 86 biosimilars. Among the US, European and Canadian markets, Amgen and Sandoz are tied in the first place with 13 approved biosimilars each. Samsung Biologics has nine approved biosimilars, followed by Pfizer with eight and Biocon Biologics with seven. In the first half of this year, FDA set a record by approving eight biosimilars — the highest for H1 of any year. EMA has okayed six biosimilars so far in 2024.In 2023, five biosimilars were approved by the FDA with just one being okayed in the first half. The year marked the end of exclusivity for Humira after 20 years, in which it netted a total of US$ 200 billion in sales. AbbVie’s flagship autoimmune drug has a record 10 biosimilars.Johnson & Johnson’s Stelara also lost exclusivity in 2023 and as many as 11 drugmakers hope to bring its biosimilars to the market. Amgen’s Wezlana was the first biosimilar to Stelara, and it was approved as interchangeable by FDA in October last year.Access the Interactive Dashboard for Biosimilar Developments (Free Excel) FDA approves first interchangeable biosimilar for Eylea, cuts regulatory feeDeveloping a biosimilar costs both money and time. According to Pfizer, developing a biosimilar can take five to nine years and cost over US$ 100 million, not including regulatory fees.In October 2023, FDA slashed its fees with the program fee at US$ 177,397, down from US$ 304,162. The application fees for products that require clinical data has been set at US$ 1,018,753, down from US$ 1,746,745. The application fee for products that don’t require clinical data has been set lower — at US$ 509,377 — down from US$ 873,373 set earlier. This reduction in application fee has propelled demand for contract manufacturing of biosimilars.There has also been a rise in approvals of interchangeable biosimilars this year. Interchangeable biosimilars meet additional requirements and may be substituted for its reference product by a pharmacist without consulting the prescriber. This year saw FDA approve the first interchangeable biosimilars for bone cancer drug denosumab (Prolia and Xgeva) in Jubbonti and Wyost as well as for eculizumab (Soliris) in Bkemv.In May, FDA approved the first interchangeable biosimilars for eye drug aflibercept (Eylea) in Opuviz and Yesafili. Other biosimilars approved in 2024 include Simlandi for adalimumab (Humira), Tyenne for tocilizumab (Actemra), Selarsdi for ustekinumab (Stelara), and Hercessi for trastuzumab (Herceptin).Access the Interactive Dashboard for Biosimilar Developments (Free Excel) Merck’s Keytruda, BMS’ Opdivo, Novartis’ Cosentyx brace for biosimilar competitionHealthcare spending in the US is projected to rise from US$ 4.5 trillion in 2022 to US$ 6 trillion by 2027. While biologics involve just two percent of prescriptions, they account for 46 percent of all pharmaceutical spending. In 2022, US$ 252 billion was spent on biologics.Biosimilar-related savings in 2023 were estimated to be US$ 9.4 billion in the US and € 10 billion (US$ 10.68 billion) in Europe. With expensive and widely used drugs like AbbVie’s Humira, J&J’s Stelara, and Regeneron’s Eylea coming under competition, US savings are projected to reach US$ 181 billion through 2027. Between 2026 and 2032, about 39 blockbusters are set to lose exclusivity in the US and Europe. Merck’s Keytruda (pembrolizumab) was the world’s top-selling drug last year, generating US$ 25 billion in sales. Its patent is set to expire in 2028 with sales expected to drop 19 percent to US$ 27.4 billion in 2029 from US$ 33.7 billion the previous year. Samsung Bioepis and Amgen initiated phase 3 trials of pembrolizumab in April and May of this year, respectively.Opdivo (nivolumab), belonging to the same class of drugs, competes with Keytruda and is also set to lose patent protection in 2028. It hauled in US$ 10 billion in total global sales in 2023 for Bristol Myers Squibb. The key patents of Novartis’ Cosentyx (secukinumab) are set to expire between 2025 and 2026. Cosentyx saw sales of US$ 5 billion in 2023. Taizhou Mabtech Pharmaceutical and Bio-Thera Solutions are conducting phase 3 trials of secukinumab.Access the Interactive Dashboard for Biosimilar Developments (Free Excel) Our viewWith over 2 billion people worldwide unable to access life-saving medicines, biosimilars hold the key to healthcare accessibility. In 2023, a record 13 biosimilars were launched in the market — the highest for a single year. And this included nine much-anticipated biosimilars to AbbVie’s Humira. In April this year, FDA announced a Biosimilars Action Plan to streamline the development of biosimilars. With a sharp focus on biosimilars, we expect more records to be broken in the near term. New launches of biosimilars to drugs like J&J’s Stelara, Regeneron’s Eylea and Merck’s Keytruda will surely help in creating new records.

Impressions: 4424

NEWS #PharmaBuzz

Dr. Reddy's Q4 Revenue Decreases By 11.51%, PAT Plunges 86%

12 May 2026

// BUSINESS STD

Dr. Reddy's To Join HSBC, Bank Of America Investor Conferences

12 May 2026

// INDPHARMAPOST

Dr. Reddy's, Nestlé Bolster Diabetes, Obesity Nutrition space

08 May 2026

// ECONOMICTIMES

Dr. Reddy’s Generics Empagliflozin Receives Tentative Nod in US

07 May 2026

// FDA

Dr Reddy's Laboratories Receives Approval From Health Canada

29 Apr 2026

// PRESS RELEASE

Onesource Pharma, Dr Reddy's Secure Health Canada Nod

29 Apr 2026

// INDPHARMAPOST

ALL APIs

Click the button for full data set

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Only 10 entries up to this point, click to access all

LISTED APIs

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

Europe

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KEY PRODUCTS

TOP RANKED SUPPLIER FOR:

Inspections and registrations

Check the inspections & registration from this company

FDA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EDQM

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

GDUFA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

THIRD-PARTY AUDIT

Eurofins Assurance: Ensuring compliance, quality, and safety with expert inspection and certification.

01 Eurofins Assurance

Belgium

Get Site Audit

CPhI Milan

Exhibiting

Eurofins Assurance: Ensuring compliance, quality, and safety with expert inspection and certification.

Dr Reddy's Laboratories Ltd

Country : United Kingdom

City/Region : MIRFIELD, WEST YORKSHIRE

Audit Date : 2026-06-16

Audit Type : On-Site

02 Eurofins Assurance

Belgium

Get Site Audit

CPhI Milan

Exhibiting

Eurofins Assurance: Ensuring compliance, quality, and safety with expert inspection and certification.

Dr. Reddy's Laboratories

Country : India

City/Region : Bollaram Village

Audit Date : 2024-06-05

Audit Type : On-Site

03 Eurofins Assurance

Belgium

Get Site Audit

CPhI Milan

Exhibiting

Eurofins Assurance: Ensuring compliance, quality, and safety with expert inspection and certification.

Industrias Químicas Falcon de México, S.A. de C.V. (Dr Reddy's)

Country : Mexico

City/Region : Jiutepec

Audit Date : 2024-03-05

Audit Type : On-Site

04 AuditGMP Pharma

Spain

Get Site Audit

CPhI Milan

Attending

AuditGMP Pharma SL delivers ISO 17020-accredited GMP audits and compliance services with expert, reliable, and tailored solutions.

Dr. Reddy's Laboratories Limited, CTO-SEZ Process Unit-01

Country : India

City/Region : Ranasthalam Mandal, Srikakulam district

Audit Date : Sep-23

Audit Type : On-Site

05 AuditGMP Pharma

Spain

Get Site Audit

CPhI Milan

Attending

AuditGMP Pharma SL delivers ISO 17020-accredited GMP audits and compliance services with expert, reliable, and tailored solutions.

Dr. Reddy's Laboratories Ltd. - Chemical Technical Operations Unit V

Country : India

City/Region : Nalgonda

Audit Date : May-24

Audit Type : On-Site

06 AuditGMP Pharma

Spain

Get Site Audit

CPhI Milan

Attending

AuditGMP Pharma SL delivers ISO 17020-accredited GMP audits and compliance services with expert, reliable, and tailored solutions.

Dr. Reddy's Laboratories Ltd. - API Hyderabad Plant 1

Country : India

City/Region : Bollaram Village, Jinnaram (Mandal)

Audit Date : Mar-26

Audit Type : On-Site

07 AuditGMP Pharma

Spain

Get Site Audit

CPhI Milan

Attending

AuditGMP Pharma SL delivers ISO 17020-accredited GMP audits and compliance services with expert, reliable, and tailored solutions.

Dr. Reddy's Laboratories Ltd. - Srikakulam Site (CTO-VI)

Country : India

City/Region : Srikakulam District

Audit Date : Jan-26

Audit Type : On-Site

08 AuditGMP Pharma

Spain

Get Site Audit

CPhI Milan

Attending

AuditGMP Pharma SL delivers ISO 17020-accredited GMP audits and compliance services with expert, reliable, and tailored solutions.

Dr. Reddy's Laboratories Ltd. - Chemical Technical Operations, Unit II

Country : India

City/Region : Bollaram, Jinnaram (Mandal)

Audit Date : Feb-24

Audit Type : On-Site

09 AuditGMP Pharma

Spain

Get Site Audit

CPhI Milan

Attending

AuditGMP Pharma SL delivers ISO 17020-accredited GMP audits and compliance services with expert, reliable, and tailored solutions.

Dr. Reddy's Laboratories Limited, CTO-SEZ Process Unit-01

Country : India

City/Region : Ranasthalam Mandal, Srikakulam district

Audit Date : Aug-26

Audit Type : On-Site

10 AuditGMP Pharma

Spain

Get Site Audit

CPhI Milan

Attending

AuditGMP Pharma SL delivers ISO 17020-accredited GMP audits and compliance services with expert, reliable, and tailored solutions.

Dr. Reddy's Laboratories Ltd. - API Hyderabad Plant 1

Country : India

City/Region : Bollaram Village, Jinnaram (Mandal)

Audit Date : Aug-23

Audit Type : On-Site

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Contact DR REDDY'S LABORATORIES LTD and get a quotation

DR REDDY'S LABORATORIES LTD is a supplier offers 255 products (APIs, Excipients or Intermediates).

Find Capecitabine bulk with DMF, CEP, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Clopidogrel bulk with DMF, CEP, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Fexofenadine Hydrochloride bulk with DMF, CEP, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Gemcitabine bulk with DMF, CEP, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Montelukast Sodium bulk with DMF, CEP, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Nizatidine bulk with DMF, CEP, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Ondansetron Hydrochloride bulk with DMF, CEP, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Quetiapine Hemifumarate bulk with DMF, CEP, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Rabeprazole Sodium bulk with DMF, CEP, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Risperidone bulk with DMF, CEP, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Rivaroxaban bulk with DMF, CEP, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Valsartan bulk with DMF, CEP, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Atorvastatin bulk with DMF, CEP, JDMF offered by DR REDDY'S LABORATORIES LTD

Find Amlodipine Besylate bulk with DMF, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Azacitidine bulk with DMF, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Carfilzomib bulk with DMF, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Cetirizine Dihydrochloride bulk with DMF, CEP, WC offered by DR REDDY'S LABORATORIES LTD

Find Clopidogrel bulk with DMF, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Dasatinib bulk with DMF, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Esomeprazole Magnesium bulk with DMF, CEP, WC offered by DR REDDY'S LABORATORIES LTD

Find Famotidine bulk with DMF, CEP, WC offered by DR REDDY'S LABORATORIES LTD

Find Finasteride bulk with DMF, CEP, JDMF offered by DR REDDY'S LABORATORIES LTD

Find Lenalidomide bulk with DMF, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Levetiracetam bulk with DMF, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Losartan Potassium bulk with DMF, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Naproxen bulk with DMF, CEP, JDMF offered by DR REDDY'S LABORATORIES LTD

Find Naratriptan Hydrochloride bulk with DMF, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Omeprazole bulk with DMF, CEP, WC offered by DR REDDY'S LABORATORIES LTD

Find Omeprazole Magnesium bulk with DMF, CEP, WC offered by DR REDDY'S LABORATORIES LTD

Find Pantoprazole Sodium bulk with DMF, CEP, WC offered by DR REDDY'S LABORATORIES LTD

Find Pioglitazone Hydrochloride bulk with DMF, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Rabeprazole Sodium bulk with DMF, CEP, WC offered by DR REDDY'S LABORATORIES LTD

Find Rivastigmine Tartrate bulk with DMF, CEP, WC offered by DR REDDY'S LABORATORIES LTD

Find Sugammadex Sodium bulk with DMF, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Sumatriptan bulk with DMF, JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Ticagrelor bulk with DMF, CEP, WC offered by DR REDDY'S LABORATORIES LTD

Find Atorvastatin bulk with DMF, JDMF offered by DR REDDY'S LABORATORIES LTD

Find Ketorolac Trometamol bulk with DMF, CEP offered by DR REDDY'S LABORATORIES LTD

Find Abiraterone Acetate bulk with DMF, JDMF offered by DR REDDY'S LABORATORIES LTD

Find Bendamustine Hydrochloride bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Bortezomib bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Cabazitaxel bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Cinacalcet Hydrochloride bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Dabigatran Etexilate Mesylate bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Dasatinib bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Decitabine bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Enzalutamide bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Eslicarbazepine Acetate bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Eszopiclone bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Fexofenadine Hydrochloride bulk with DMF, CEP offered by DR REDDY'S LABORATORIES LTD

Find Gatifloxacin bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Glimepiride bulk with DMF, CEP offered by DR REDDY'S LABORATORIES LTD

Find Lenvatinib Mesylate bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Levocetirizine Dihydrochloride bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Linagliptin bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Lomustine bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Lurasidone Hydrochloride bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Midostaurin bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Naproxen bulk with DMF, CEP offered by DR REDDY'S LABORATORIES LTD

Find Naproxen Sodium bulk with DMF, CEP offered by DR REDDY'S LABORATORIES LTD

Find Nilotinib bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Omeprazole bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Omeprazole Magnesium bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Ondansetron bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Ondansetron Hydrochloride bulk with JDMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Palonosetron bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Pantoprazole Sodium bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Pemetrexed Disodium bulk with DMF, CEP offered by DR REDDY'S LABORATORIES LTD

Find Permethrin bulk with DMF, CEP offered by DR REDDY'S LABORATORIES LTD

Find Pomalidomide bulk with DMF, JDMF offered by DR REDDY'S LABORATORIES LTD

Find Pregabalin bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Raloxifene Hydrochloride bulk with DMF, CEP offered by DR REDDY'S LABORATORIES LTD

Find Ramipril bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Roxadustat bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Sitagliptin Phosphate bulk with DMF, CEP offered by DR REDDY'S LABORATORIES LTD

Find Terbinafine Hydrochloride bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Tizanidine Hydrochloride bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Ziprasidone Hydrochloride bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Zoledronic Acid bulk with DMF, WC offered by DR REDDY'S LABORATORIES LTD

Find Apalutamide bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Apixaban bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Apremilast bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Atomoxetine bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Bempedoic Acid bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Cabozantinib bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Dapagliflozin bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Dapagliflozin Propanediol Monohydrate bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Edaravone bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Empagliflozin bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Ferric Carboxymaltose bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Fosaprepitant bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Iron Sucrose bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Levofloxacin Hemihydrate bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Lumateperone Tosylate bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Metoprolol Succinate bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Olaparib bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Posaconazole bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Sacubitril-Valsartan bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Tofacitinib Citrate bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Ziprasidone Hydrochloride bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Atorvastatin bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Benztropine bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Cetirizine Dihydrochloride bulk with CEP offered by DR REDDY'S LABORATORIES LTD

Find Clopidogrel bulk with WC offered by DR REDDY'S LABORATORIES LTD

Find Dabigatran Etexilate Mesylate bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Decitabine bulk with WC offered by DR REDDY'S LABORATORIES LTD

Find Deucravacitinib bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Donepezil bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Doxazosin Mesylate bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Dutasteride bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Edoxaban Tosylate bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Enzalutamide bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Eribulin bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Esomeprazole Magnesium bulk with WC offered by DR REDDY'S LABORATORIES LTD

Find Ezetimibe bulk with WC offered by DR REDDY'S LABORATORIES LTD

Find Fondaparinux Sodium bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Granisetron bulk with WC offered by DR REDDY'S LABORATORIES LTD

Find Lacidipine bulk with WC offered by DR REDDY'S LABORATORIES LTD

Find Lenalidomide bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Lifitegrast bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Liraglutide bulk with WC offered by DR REDDY'S LABORATORIES LTD

Find Memantine Hydrochloride bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Mirabegron bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Moxifloxacin Hydrochloride bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Naproxen bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Nilotinib bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Omeprazole bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Palbociclib bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Pantoprazole Sodium bulk with WC offered by DR REDDY'S LABORATORIES LTD

Find Pazopanib Hydrochloride bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Pregabalin bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Rabeprazole Sodium bulk with WC offered by DR REDDY'S LABORATORIES LTD

Find Relugolix bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Ripretinib bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Rivaroxaban bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Roxadustat bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Semaglutide bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Sitagliptin Hydrochloride bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Sitagliptin Phosphate bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Sumatriptan bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Testosterone bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Tizanidine Hydrochloride bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Travoprost bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Tucatinib bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Valsartan bulk with JDMF offered by DR REDDY'S LABORATORIES LTD

Find Varenicline Tartrate bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Venetoclax bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Voclosporin bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Vonoprazan Fumarate bulk with DMF offered by DR REDDY'S LABORATORIES LTD

Find Capecitabine bulk offered by DR REDDY'S LABORATORIES LTD

Find Dimethyl Fumarate bulk offered by DR REDDY'S LABORATORIES LTD

Find Elagolix Sodium bulk offered by DR REDDY'S LABORATORIES LTD

Find Ketorolac Trometamol bulk offered by DR REDDY'S LABORATORIES LTD

Find Metoprolol Succinate bulk offered by DR REDDY'S LABORATORIES LTD

Find Siponimod fumarate bulk offered by DR REDDY'S LABORATORIES LTD

Find Abacavir Sulfate bulk offered by DR REDDY'S LABORATORIES LTD

Find Acalabrutinib bulk offered by DR REDDY'S LABORATORIES LTD

Find Acoramidis Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Adagrasib bulk offered by DR REDDY'S LABORATORIES LTD

Find Alendronate Sodium bulk offered by DR REDDY'S LABORATORIES LTD

Find Amlodipine Besylate bulk offered by DR REDDY'S LABORATORIES LTD

Find Anastrozole bulk offered by DR REDDY'S LABORATORIES LTD

Find Apixaban bulk offered by DR REDDY'S LABORATORIES LTD

Find Aprepitant bulk offered by DR REDDY'S LABORATORIES LTD

Find Asenapine Maleate bulk offered by DR REDDY'S LABORATORIES LTD

Find Atorvastatin bulk offered by DR REDDY'S LABORATORIES LTD

Find Bazedoxifene Acetate bulk offered by DR REDDY'S LABORATORIES LTD

Find Belumosudil bulk offered by DR REDDY'S LABORATORIES LTD

Find Bivalirudin bulk offered by DR REDDY'S LABORATORIES LTD

Find Brensocatib bulk offered by DR REDDY'S LABORATORIES LTD

Find Canagliflozin bulk offered by DR REDDY'S LABORATORIES LTD

Find Capivasertib bulk offered by DR REDDY'S LABORATORIES LTD

Find Carvedilol bulk offered by DR REDDY'S LABORATORIES LTD

Find CAS 654671-77-9 bulk offered by DR REDDY'S LABORATORIES LTD

Find Cetirizine bulk offered by DR REDDY'S LABORATORIES LTD

Find Cetirizine Dihydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Ciprofloxacin Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Citalopram Hydrobromide bulk offered by DR REDDY'S LABORATORIES LTD

Find Clopidogrel bulk offered by DR REDDY'S LABORATORIES LTD

Find Clopidogrel Besylate bulk offered by DR REDDY'S LABORATORIES LTD

Find Dapagliflozin Propanediol Monohydrate bulk offered by DR REDDY'S LABORATORIES LTD

Find Darolutamide bulk offered by DR REDDY'S LABORATORIES LTD

Find Desloratadine bulk offered by DR REDDY'S LABORATORIES LTD

Find Dexlansoprazole bulk offered by DR REDDY'S LABORATORIES LTD

Find Diroximel fumarate bulk offered by DR REDDY'S LABORATORIES LTD

Find Divalproex Sodium bulk offered by DR REDDY'S LABORATORIES LTD

Find Duloxetine Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Dutasteride bulk offered by DR REDDY'S LABORATORIES LTD

Find Elinzanetant bulk offered by DR REDDY'S LABORATORIES LTD

Find Empagliflozin bulk offered by DR REDDY'S LABORATORIES LTD

Find Enalapril Maleate bulk offered by DR REDDY'S LABORATORIES LTD

Find Enzalutamide bulk offered by DR REDDY'S LABORATORIES LTD

Find Escitalopram Oxalate bulk offered by DR REDDY'S LABORATORIES LTD

Find Everolimus bulk offered by DR REDDY'S LABORATORIES LTD

Find Febuxostat bulk offered by DR REDDY'S LABORATORIES LTD

Find Fluconazole bulk offered by DR REDDY'S LABORATORIES LTD

Find Fluoxetine Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Fruquintinib bulk offered by DR REDDY'S LABORATORIES LTD

Find Galantamine Hydrobromide bulk offered by DR REDDY'S LABORATORIES LTD

Find Gemcitabine bulk offered by DR REDDY'S LABORATORIES LTD

Find Glatiramer Acetate bulk offered by DR REDDY'S LABORATORIES LTD

Find Hydroxychloroquine Sulphate bulk offered by DR REDDY'S LABORATORIES LTD

Find Ibandronate Sodium bulk offered by DR REDDY'S LABORATORIES LTD

Find Icatibant Acetate bulk offered by DR REDDY'S LABORATORIES LTD

Find Imatinib Mesylate bulk offered by DR REDDY'S LABORATORIES LTD

Find Iptacopan Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Irbesartan bulk offered by DR REDDY'S LABORATORIES LTD

Find Letrozole bulk offered by DR REDDY'S LABORATORIES LTD

Find Linezolid bulk offered by DR REDDY'S LABORATORIES LTD

Find Lubiprostone bulk offered by DR REDDY'S LABORATORIES LTD

Find Milnacipran Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Moxifloxacin Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Naproxen Sodium bulk offered by DR REDDY'S LABORATORIES LTD

Find Nateglinide bulk offered by DR REDDY'S LABORATORIES LTD

Find Nicotinamide Riboside Chloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Nizatidine bulk offered by DR REDDY'S LABORATORIES LTD

Find Olanzapine bulk offered by DR REDDY'S LABORATORIES LTD

Find Omeprazole bulk offered by DR REDDY'S LABORATORIES LTD

Find Orforglipron Calcium Hydrate bulk offered by DR REDDY'S LABORATORIES LTD

Find Oxaprozin bulk offered by DR REDDY'S LABORATORIES LTD

Find Paliperidone bulk offered by DR REDDY'S LABORATORIES LTD

Find Paliperidone Palmitate bulk offered by DR REDDY'S LABORATORIES LTD

Find Pemetrexed Ditromethamine bulk offered by DR REDDY'S LABORATORIES LTD

Find Perfluorohexyloctane bulk offered by DR REDDY'S LABORATORIES LTD

Find Pioglitazone bulk offered by DR REDDY'S LABORATORIES LTD

Find Pirtobrutinib bulk offered by DR REDDY'S LABORATORIES LTD

Find Plerixafor bulk offered by DR REDDY'S LABORATORIES LTD

Find Prasugrel Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Pregabalin bulk offered by DR REDDY'S LABORATORIES LTD

Find Primidone bulk offered by DR REDDY'S LABORATORIES LTD

Find Resmetirom bulk offered by DR REDDY'S LABORATORIES LTD

Find Risperidone bulk offered by DR REDDY'S LABORATORIES LTD

Find Ropinirole bulk offered by DR REDDY'S LABORATORIES LTD

Find Ropinirole Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Sacubitril-Valsartan bulk offered by DR REDDY'S LABORATORIES LTD

Find Saxagliptin Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Seladelpar Lysine bulk offered by DR REDDY'S LABORATORIES LTD

Find Siponimod bulk offered by DR REDDY'S LABORATORIES LTD

Find Sitagliptin Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Sitagliptin Malate bulk offered by DR REDDY'S LABORATORIES LTD

Find Sugammadex Sodium bulk offered by DR REDDY'S LABORATORIES LTD

Find Tafamidis bulk offered by DR REDDY'S LABORATORIES LTD

Find Terbinafine Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Tolterodine Tartrate bulk offered by DR REDDY'S LABORATORIES LTD

Find Topiramate bulk offered by DR REDDY'S LABORATORIES LTD

Find Treprostinil Sodium bulk offered by DR REDDY'S LABORATORIES LTD

Find Udenafil bulk offered by DR REDDY'S LABORATORIES LTD

Find Upadacitinib bulk offered by DR REDDY'S LABORATORIES LTD

Find Valganciclovir Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Valsartan bulk offered by DR REDDY'S LABORATORIES LTD

Find Venlafaxine Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Vilazodone Hydrochloride bulk offered by DR REDDY'S LABORATORIES LTD

Find Voriconazole bulk offered by DR REDDY'S LABORATORIES LTD

Find Xanomeline bulk offered by DR REDDY'S LABORATORIES LTD

Find Zafirlukast bulk offered by DR REDDY'S LABORATORIES LTD

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Company profile for Dr. Reddy's Laboratories

VIRTUAL BOOTH

CONTACT DETAILS

Google Map, LinkedIn, Emails...

EVENTS

Webinars & Exhibitions

DIGITAL CONTENT

2 Vlog #PharmaReel

8 Corporate Content #SupplierSpotlight

12 Data Compilation #PharmaFlow

1111 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

330 All APIs

162 USDMF

40 CEP/COS

34 JDMF

114 EU WC

145 KDMF

155 NDC API

146 Listed APIs

DEVELOPMENTS

401 Drugs in Development

FINISHED DOSAGE FORMULATIONS

837 FDF Dossiers

595 FDA Orange Book

5 Europe

58 Canada

179 Listed Dossiers

KEY PRODUCTS

INSPECTIONS & REGISTRATIONS

83 FDA

36 EDQM

18 GDUFA

10 Third-Party Audit

01

02

03

04

05

06

07

08

09

10

What are you looking for?